ORION CLASS B news, videos and press releases - Page 3
For more news please use our advanced search feature.
ORION CLASS B - More news...
ORION CLASS B - More news...
- Orion Corporation: Managers’ transactions – Jari Karlson
- Orion Corporation: Transfer of 150,118 own B shares on 1 March 2024
- Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published
- Orion and Save the Children Finland announce cooperation to promote well-being of children in Finland and globally
- Orion to investigate the possible outsourcing of its pharmaceutical production in Kuopio, Finland
- Notice to the Annual General Meeting of Orion Corporation
- Orion Group Financial Statement Release January–December 2023
- 119,021 Orion Corporation A shares converted into B shares
- Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024
- Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain
- Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
- Change in Orion Group Executive Management Board – René Lindell appointed Chief Financial Officer of Orion
- Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting
- Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31 million positive impact on Orion’s result in 2023
- Orion Corporation: Managers’ transactions – Ari Lehtoranta
- Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
- Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
- NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
- 87 000 Orion Corporation A shares converted into B shares
- Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov database
- Orion Animal Health receives FDA approval for Bonqat® (pregabalin oral solution)
- Orion Corporation: Managers’ transactions – Agendum Oy
- Orion Corporation: Managers’ transactions – Mikael Silvennoinen
- Orion Research Foundation grants EUR 1,112,000 for research in 2024
